Interview: Medicines for Europe Reports on EU Biosimilar Success

27 July 2020

The Center for Biosimilars® (CfB) spoke with Adrian van den Hoven, […]

Christoph Stoller and Adrian van den Hoven interviewed by PharmaBoardroom

17 July 2020

In the wake of the publication of Medicines for Europe’s Lessons […]

Resolving and mitigating medicine shortages in the EU

10 February 2020

Drug shortages can greatly impact patients and the pharmaceutical industry. […]

Biosimilar Uptake in Europe: Big Challenges; Bigger Rewards

16 January 2020

Since the first treatment was approved in 2006, Europe has […]

Biosimilars ‒ Policy failings that deny savings to countries that need it most

21 November 2019

Future and Challenges of the Pharmaceutical Industry

14 November 2019

Interview: Adrian van den Hoven, Director General of Medicines for Europe

8 January 2019

Over the last ten years, generic medicines have increased access […]

SPC manufacturing waiver is good news for Europe

19 September 2018

An SPC manufacturing waiver should be extremely beneficial for Europe […]

Analysis of the proposal for a regulation of a manufacturing exception related to the SPC and aimed to make the European industry competitive

13 September 2018

Andriukaitis: SPC manufacturing waiver does not damage pharma innovation

12 June 2018